Michael Craig Pine - 05 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Corp Dev.&Strat. Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
05 Jan 2024
Net transactions value
-$121,706
Form type
4
Filing time
09 Jan 2024, 21:11:46 UTC
Previous filing
11 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +15,285 +352% $0.000000 19,628 06 Jan 2024 Direct
transaction EYPT Common Stock Tax liability $121,706 -5,966 -30% $20.40 13,662 06 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +21,000 $0.000000 21,000 05 Jan 2024 Common Stock 21,000 $0.000000 Direct F2
transaction EYPT Stock Option (Right to Buy) Award $0 +42,000 $0.000000 42,000 05 Jan 2024 Common Stock 42,000 $20.40 Direct F3
transaction EYPT Restricted Stock Units Options Exercise $0 -15,285 -33% $0.000000 30,570 06 Jan 2024 Common Stock 15,285 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2 The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.
F3 The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.
F4 The restricted stock units vests in three ratable annual installments beginning January 6, 2024.